ONWARD Medical

🎉 We're thrilled to announce we have exclusively licensed Commissariat a l'Energie Atomique et aux Energies Alternatives’s Brain-Computer Interface (BCI) technology! This strengthens our opportunity to be first-to-market with a BCI-enabled system to restore thought-driven movement after paralysis. The agreement gives us exclusive rights to incorporate Clinatec's investigational WIMAGINE® BCI into our investigational ARC-BCI™ System and extends our leadership in the effort to develop and commercialize BCI-enabled therapies to restore thought-driven movement of the human body after paralysis. ✨ Integrating Clinatec’s BCI with our investigational ARC-IM System creates a #DigitalBridge™ that wirelessly bypasses the injured part of the spinal cord to restore brain-to-body communication. Imagine a future in which thoughts can drive movement after paralysis, empowering individuals to reclaim control and independence never before possible. The WIMAGINE BCI has 7 years of human safety data and ONWARD ARC-IM Therapy has now been applied in more than 30 study participants. We recently announced the third successful implant of ARC-BCI Therapy to restore thought-driven movement after spinal cord injury (SCI).  Our BCI development leverages the world-class expertise of #Clinatec and .NeuroRestore and is funded by the Christopher & Dana Reeve Foundationand the European Innovation Council and SMEs Executive Agency (EISMEA).  🔗 For more details, click on our press release below ⬇️ 🙏 We are grateful to deepen our collaboration with the leader in BCI technology and look forward to sharing future updates on our continued progress along this exciting frontier! Special thanks to Julie Galland, Guillaume CHARVET, Sébastien Dauvé. Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

💫 Scientific innovation in #neurotech took the world diplomatic stage last month as our co-founders and advisors, neuroscientist G. Courtine and neurosurgeon Jocelyne Bloch, addressed the United Nations Security Council. 🇺🇳    The pair shared their knowledge about the latest breakthroughs in brain-computer interface (BCI) technology, leveraging their groundbreaking work developing a DigitalBridge™ to enable though-driven movement after paralysis.     The Security Council discussed how scientific developments can contribute to global peace and security. Swiss Federal Councillor Ignazio Cassis, chaired the meeting after Switzerland introduced the topic for Council discussions.🇨🇭    The opportunity highlights the profound impact scientific advances can make on daily lives and world affairs. We feel privileged that our co-founders and collaborators were part of this important conversation. 🌏    #EmpoweringMovement #SCI #BCI #UNSecurityCouncil #WorldPeace    Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.  

⭐️ Thank you, STAT and Timmy Broderick , for your in-depth coverage of our mission and our therapies. In an article titled, “Buoyed by Clinical Success, ONWARD Medical Charts Future of Neurostimulation,” Broderick takes a deep dive into neurostimulation and its potential to address the challenges that confront people with spinal cord injury (SCI). Broderick, a Disability in Health Care Reporting Fellow at STAT, spoke extensively with our CEO Dave Marver about our plans for commercialization. Broderick also shared the story of our Up-LIFT trial participant Sherown Campbell, who told STAT that his experience with our non-invasive investigational ARC-EX® Therapy “was a great step in my recovery.” The pair kicked off the STAT Summit last month by sitting down with reporter Lizzy Lawrence in a keynote conversation called “Helping Paralyzed People Move.” 🎤 ✨We are truly impressed with the level of attention, care, and curiosity STAT demonstrated to get the story right, both on stage and in print. 🔗 Link to article in comments. #EmpoweringMovement #SCI #STATSummit Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

🎉 Three years ago, we made history with the largest pre-revenue medtech IPO in Europe...ever. Since then, we’ve been on an incredible journey fueled by a strong team, loyal investors and committed partners. We’ve grown from a promising startup to a company on the brink of commercialization. As we reflect on the milestones since our Euronext public listing in October 2021, we’re excited to share some of our most notable achievements: Innovation ✅ Accrued 278 issued patents, strengthening and protecting our first-mover advantage ✅ Awarded 10 US FDA Breakthrough Device Designations across our ARC-EX, ARC-IM, and ARC-BCI platforms Technological ✅ Completed initial development of the investigational ARC-IM® Neurostimulator, which has been implanted in humans in clinical feasibility studies since May 2022 ✅ Completed initial development of the ARC-IM Lead, which has been implanted in humans in clinical feasibility studies since May 2023 ✅ Completed initial development of the investigational ARC-BCI™ System, which has been implanted in humans in clinical feasibility studies since late 2023 Corporate ✅ Awarded a grant from our strategic partner, the Christopher & Dana Reeve Foundation, supporting our work using brain-computer interface (BCI) technology ✅ Completed a 20M Euro capital raise in March 2024, and a financing agreement with Runway Growth Capital in June 2024, providing up to EUR 52.5M in additional capital over the next few years to fund upcoming milestones ✅  Successfully raised 50M Euro in new funding in October 2024, led by a cornerstone investment from Ottobock, a global leader in prosthetics, orthotics, and exoskeleton technology ✅ Gained equity research coverage from Stifel Financial Corp., Bryan, Garnier & Co, KBC Securities, Degroof Petercam, and Kepler Cheuvreux Clinical ✅ Submitted a De Novo application to the US Food and Drug Administration (FDA) for our investigational ARC-EX® System ✅ Published results of our Up-LIFT pivotal trial for ARC-EX Therapy in Nature Medicine ✅ Conducted several clinical feasibility studies for our ARC-IM Therapy, exploring the use of our ARC-IM® System to restore movement and autonomic function after SCI and Parkinson’s disease ✅ Paired our ARC-IM System with an implanted brain-computer interface (BCI) to enable thought-driven movement ✨ We are grateful to Euronext and our investors for supporting our goal to serve the SCI community with breakthrough solutions. Your belief in our vision demonstrates the importance of investment to drive innovation. 🚀 #EmpoweringMovement #SCI #IPOanniversary Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

🛎️ We are delighted to share that we have raised EUR 50 million in new funding, led by a cornerstone investment from Ottobock, a global leader in prosthetics, orthotics, and exoskeleton technology with 9,000 employees and operations in almost 60 countries. Here are the headlines:  ⭐️ This investment initiates a long-term strategic relationship with Ottobock, which has more than 100 years of experience serving people with movement disabilities. ⭐️ This financing extends our cash runway to two years or more, providing ample capital to fuel our transition to a commercial enterprise, and to achieve our many planned development, clinical, and operations milestones. ⭐️ With this financing completed, we look forward to collaborating with Ottobock across a range of development and commercial activities.   Thank you to our advisors at UBS, Skadden Law Firm, Bryan, Garnier & Co, NautaDutilh, Degroof Petercam, and KBC Securities for assisting with this transaction.  🔗 For more details on the capital raise, click on the link for our press release in the comments.  This additional capital will help us achieve our mission to restore movement, function, and independence to the millions of people with spinal cord injuries and movement disabilities around the globe. Thank you to our new and longstanding investors who are supporting us in this pursuit. ✨ #EmpoweringMovement #SCI #CapitalRaise Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.   

🎉 We are delighted to announce additions to our Board of Directors, including a new incoming Chairman! These individuals will help power our evolution to a commercial-stage company.  ⭐️ Rob ten Hoedt, a well-respected MedTech leader, and Rahma Samow, a digital health and direct-to-consumer business expert, will join our Board of Directors. Rob will also become Chairman at year-end following the planned retirement of current Director and Chairman Jan Øhrstrøm after eight years of appreciated service. In addition, we are bidding farewell to longtime Director Fred Colen, who is also retiring from the Board at the end of the year. ⭐ Rob most recently served as President and Executive Committee member at Medtronic, the world’s largest medical device company. He also served as longtime Chairman of MedTech Europe, the largest trade association representing medical technology companies in Europe.  Rob brings an impressive record of accomplishment in technology development, business-model innovation, and commercial excellence that will help us achieve our full potential as a pioneering company. ⭐️ Rahma is currently President and CEO of ClearChoice Dental Implant Centers, a fast-growing, US-based leader in dental implant therapy and tooth replacement services, with more than 2,000 employees. Prior to ClearChoice, Rahma served on the Executive Management Board of Swiss-based Straumann Group following a 15-year career with Siemens Healthineers. Rahma’s vast business experience and passion for building patient communities and connecting directly with those with injuries and their families will help drive our commercial strategy moving forward. ⭐️ We thank Jan for his outstanding stewardship of the Board and Company during a robust period of growth. Over his eight-year tenure as Board Chair, we have reached significant scientific and clinical milestones and have transformed into a public company. ⭐️ We also thank Fred for his many years of service to the Board and Company. Since 2016, Fred has offered his experience as a MedTech R&D and business leader to help guide the Company and our key leaders. We thank our outgoing board members for their commitment to ONWARD and are excited that new leaders of such high caliber have chosen to join us in building the new era ahead! 🚀 🔗 For more information, click on the link to the press release in the comments.   #EmpoweringMovement #SCI #BoardChanges  Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.  

“You can draw a straight line from his advocacy to developments like today. He would be the first in line to sign up for this [technology]” -ABC News correspondent Will Reeve, son of Christopher Reeve, reporting on a 2023 breakthrough using BCI technology from ONWARD® Medical research collaborators    💫 Last year, Will Reeve invoked his father’s thirst for innovation when he reported on Gert-Jan, the first paralyzed man in the world who was able to walk through the power of thought using a brain-computer interface (BCI) paired with our investigational spinal stimulation therapy.     Christopher Reeve’s relentless advocacy for the spinal cord injury (SCI) community takes center stage in the new Warner Bros. Entertainment documentary, Super/Man: The Christopher Reeve Story. That drive for innovative solutions lives on in the work of Reeve’s namesake organization, and we are proud partners with the Christopher & Dana Reeve Foundation. 🙏    Recently, we announced a grant from the Reeve Foundation for our work involving #BCI technology to help people with SCI restore thought-driven movement in their arms and hands again.    Marco Baptista, Ph.D., Chief Scientific Officer of the Christopher & Dana Reeve Foundation, said that the grant reflects the organization’s “vision to facilitate rapid scientific advancement to address the unmet needs of individuals living with SCI.”     The grant underscores Christopher Reeve’s powerful legacy, twenty years after his passing.     Marco sat down with our CEO, Dave Marver, to discuss the grant and the importance of investing in future-forward therapies to help improve the lives of those with SCI. We hope you enjoy this enlightening conversation. 🎤    Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.     #EmpoweringMovement #SCI #BCI   

Thank you Les Echos for highlighting this important milestone in our journey, illustrating how innovative solutions like #BCI will transform the future of healthcare. “Onward Medical a gagné jusqu'à 15%, signant l'une des meilleures performances en intraday de la Bourse de Paris.” Les Echos We couldn't do this without the world-class expertise of #Clinatec and .NeuroRestore, and funding from Christopher & Dana Reeve Foundation and the European Innovation Council and SMEs Executive Agency (EISMEA). Article link in comments below #EmpoweringMovement #SCI #Innovation #LesEchosInvestir    *All of ONWARD Medical's devices and therapies, including ARC-IM®, ARC-EX®, ARC-BCI™ and ARC Therapy™, alone or in combination with a brain-machine interface (BCI), are experimental and not yet commercially available. 

🎉 We’re thrilled to share that Le Figaro, a leading French media outlet, has highlighted our recent announcement of our exclusive license with Commissariat a l'Energie Atomique et aux Energies Alternatives. "Clinatec est un institut de recherche biomédicale de renommée mondiale et son BCI est idéal pour nos applications. Nous pouvons désormais développer un système véritablement intégré, parfaitement adapté au type d'étude requis pour obtenir l'approbation réglementaire et commercialiser un système activé par un BCI." Our #BCI research leverages the world-class expertise of #Clinatec and .NeuroRestore and is funded by the Christopher & Dana Reeve Foundation and the European Innovation Council and SMEs Executive Agency (EISMEA). Please note: All ONWARD® Medical devices and therapies, including ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not yet available for commercial use. Article link in the comments. #EmpoweringMovement #SCI #BCI

✨ Thank you, STAT, for the opportunity to highlight the experience of our Up-LIFT trial participant, Sherown Campbell at the #STATSummit. Sherown and our CEO, Dave Marver, joined Lizzy Lawrence on stage for a thoughtful discussion about the power of small changes that can make a big difference in improving the quality of life for those living with spinal cord injury (SCI). #EmpoweringMovement #SCI #STATSummit